{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:43:12Z","timestamp":1794775392236,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eclinm.2023.102130","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T15:35:00Z","timestamp":1692372900000},"page":"102130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study"],"prefix":"10.1016","volume":"63","author":[{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-011X","authenticated-orcid":false,"given":"Shankara","family":"Paneesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn E.","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Hrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Morley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bastos-Oreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Devizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"DeMarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0894","authenticated-orcid":false,"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102130_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2023.102130_bib2","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.eclinm.2023.102130_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102130_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-020-01018-6","article-title":"How we treat mature B-cell neoplasms (indolent B-cell lymphomas)","volume":"14","author":"Lumish","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.eclinm.2023.102130_bib5","series-title":"REVLIMID (lenalidomide) capsules for oral use [prescribing information]","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102130_bib6","series-title":"REVLIMID: summary of product characteristics","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102130_bib7","series-title":"BREYANZI (lisocabtagene maraleucel) suspension for intravenous infusion [prescribing information]","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102130_bib8","series-title":"YESCARTA (axicabtagene ciloleucel) suspension for intravenous infusion [prescribing information]","year":"2021"},{"key":"10.1016\/j.eclinm.2023.102130_bib9","series-title":"Yescarta (axicabtagene ciloleucel): summary of product characteristics","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102130_bib10","series-title":"TAZVERIK (tazemetostat) tablets, for oral use [prescribing information]","year":"2020"},{"key":"10.1016\/j.eclinm.2023.102130_bib12","series-title":"Secura Bio announces Copiktra\u00ae (duvelisib) strategic focus on T-cell lymphoma and voluntary U.S. withdrawal of the relapsed or refractory follicular lymphoma indication [press release]","year":"2021"},{"key":"10.1016\/j.eclinm.2023.102130_bib13","series-title":"TG Therapeutics announces voluntary withdrawal of the BLA\/sNDA for U2 to treat patients with CLL and SLL [press release]","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102130_bib14","author":"US Food and Drug Administration"},{"key":"10.1016\/j.eclinm.2023.102130_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/1471-2407-14-565","article-title":"Constitutive AKT activation in follicular lymphoma","volume":"14","author":"Yahiaoui","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2023.102130_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2013.087171","article-title":"Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies","volume":"99","author":"Jabbour","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2023.102130_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2020.08.022","article-title":"Can next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma?","volume":"21","author":"Phillips","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.eclinm.2023.102130_bib18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a Phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102130_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102130_bib20","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102130_bib21","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102130_bib22","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/acsmedchemlett.9b00334","article-title":"INCB050465 (parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4)","volume":"10","author":"Yue","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.eclinm.2023.102130_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.120.265538","article-title":"Parsaclisib is a next-generation phosphoinositide 3-kinase \u03b4 inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy","volume":"374","author":"Shin","year":"2020","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.eclinm.2023.102130_bib24","series-title":"Survival analysis: techniques for censored and truncated data. Springer","author":"Klein","year":"1997"},{"key":"10.1016\/j.eclinm.2023.102130_bib25","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102130_bib26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102130_bib27","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3Kdelta\/CK1epsilon inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102130_bib28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eclinm.2023.102130_bib29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.eclinm.2023.102130_bib30","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1200\/JCO.2019.37.15_suppl.7513","article-title":"MAGNIFY: phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Andorsky","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:22:35Z","timestamp":1762899755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023003073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"alternative-id":["S2589537023003073"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102130","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parsaclisib, a PI3K\u03b4 inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102130"}}